Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

National Glaucoma Research
Current Award

Dr. Anna Demetriades

Anna Demetriades, M.D., Ph.D.

Joan and Sanford I. Weill Medical College of Cornell University
New York, NY

Title: Neurotrophic Biofactories for the Treatment of Glaucoma
Non-Technical Title: New Method of Delivering Therapeutic Proteins to the Eye for the Treatment of Glaucoma

Acknowledgements: This grant is made possible in part by a gift from The New York Community Trust – Steven & Barbara Rothman Fund.
Duration: July 1, 2013 - June 30, 2015
Award Type: Standard
Award Amount: $100,000

Summary:

Glaucoma is the result of retinal ganglion cell (RGC) death in the eye which ultimately leads to vision loss in patients. RGCs are the nerve cells that extend down the optic nerve and connect the eye to the brain. The aim of this study is to develop a novel treatment for patients by identifying a new way to slow down and prevent RGC death. Dr. Demetriades’ team will use gene therapy to deliver neuroprotective proteins to specific cells within the retina and determine whether it is best to deliver these proteins directly to RGCs or to adjacent cells in order to optimally improve their survival.

Details:

The goal of this project is to develop a new gene therapy treatment for glaucoma patients aimed at slowing down or stopping disease progression.

Dr. Demetriades’ team will use a gene therapy approach to deliver neuroprotective proteins to specific cells within the retina. Retinal ganglion cell (RGC) death is the hallmark of glaucoma. The gene therapy method will deliver therapeutic proteins to RGCs and adjacent cells within the retina to improve their survival.

The innovative aspect of this proposal is the use of a cell-specific gene therapy approach. Dr. Demetriades will develop gene therapy carrier systems that enable delivery of a therapeutic protein to a specific cell type within the retina. This research could lead to the creation of a novel delivery system for the eye.

Current treatments control eye pressure but vision loss may still occur. Dr. Demetriades’ study will provide new insights into the potential of cell-specific gene therapy for the treatment of glaucoma. Their goal through this work is to develop an adjuvant therapy that slows or stops disease progression in order to prevent vision loss.